Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Antioxidative Activity after Rosuvastatin Treatment in Patients with Stable Ischemic Heart Disease and Decreased High Density Lipoprotein Cholesterol

  • Park, Do-Sim (Department of Laboratory medicine, Wonkwang University Hospital and School of Medicine) ;
  • Yun, Kyeong Ho (Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital) ;
  • Park, Hyun Young (Institute of Wonkwang Medical Science, Wonkwang University School of Medicine) ;
  • Rhee, Sang Jae (Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital) ;
  • Kim, Nam-Ho (Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital) ;
  • Oh, Seok Kyu (Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital) ;
  • Jeong, Jin-Won (Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital)
  • Received : 2015.07.17
  • Accepted : 2015.10.06
  • Published : 2016.05.30
⟨ Previous Next ⟩

Abstract

Background and Objectives: The clinical significance of statin-induced high-density lipoprotein cholesterol (HDL-C) changes is not well known. We investigated whether rosuvastatin-induced HDL-C changes can influence the anti-oxidative action of high-density lipoprotein particle. Subjects and Methods: A total of 240 patients with stable ischemic heart disease were studied. Anti-oxidative property was assessed by paraoxonase 1 (PON1) activity. We compared the lipid profile and PON1 activity at baseline and at 8 weeks after rosuvastatin 10 mg treatment. Results: Rosuvastatin treatment increased the mean HDL-C concentration by $1.9{\pm}9.2mg/dL$ ($6.4{\pm}21.4%$). HDL-C increased in 138 patients (57.5%), but decreased in 102 patients (42.5%) after statin treatment. PON1 activity increased to 19.1% in all patients. In both, the patients with increased HDL-C and with decreased HDL-C, PON1 activity significantly increased after rosuvastatin treatment (+19.3% in increased HDL-C responder; p=0.018, +18.8% in decreased HDL-C responder; p=0.045 by paired t-test). Baseline PON1 activity modestly correlated with HDL-C levels (r=0.248, p=0.009); however, the PON1 activity evaluated during the course of the treatment did not correlate with HDL-C levels (r=0.153, p=0.075). Conclusion: Rosuvastatin treatment improved the anti-oxidative properties as assessed by PON1 activity, regardless of on-treatment HDL-C levels, in patients with stable ischemic heart disease.

Keywords

Acknowledgement

Supported by : The Korean Society of Cardiology, NRF of Korea

References

  1. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Sacandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
  2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group. N Engl J Med 1995;333:1301-7. https://doi.org/10.1056/NEJM199511163332001
  3. Hong YJ, Jeong MH, Lim JH, et al. The prognostic significance of statin therapy according to the level of C-reactive protein in acute myocardial infarction patients who underwent percutaneous coronary intervention. Korean Circ J 2003;33:891-900. https://doi.org/10.4070/kcj.2003.33.10.891
  4. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009;373:1175-82. https://doi.org/10.1016/S0140-6736(09)60447-5
  5. Sim DS, Jeong MH, Cho KH, et al. Effect of early statin treatment in patients with cardiogenic shock complicating acute myocardial infarction. Korean Circ J 2013;43:100-9. https://doi.org/10.4070/kcj.2013.43.2.100
  6. Yamashita S, Tsubakio-Yamamoto K, Ohama T, Nakagawa-Toyama Y, Nishida M. Molecular mechanisms of HDL-cholesterol elevation by statins and its effects on HDL functions. J Atheroscler Thromb 2010;17:436-51. https://doi.org/10.5551/jat.5405
  7. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998;101:1581-90. https://doi.org/10.1172/JCI1649
  8. McElveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem 1986;32:671-3.
  9. Yun KH, Shin SN, Ko JS, et al. Rosuvastatin-induced high-density lipoprotein changes in patients who underwent percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome. J Cardiol 2012;60:383-8. https://doi.org/10.1016/j.jjcc.2012.07.008
  10. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012;60:1581-98. https://doi.org/10.1016/j.jacc.2012.08.001
  11. Cebeci E, Oner FA, Usta M, Yurdakul S, Erguney M. Evaluation of oxidative stress, the activities of paraoxonase and arylesterase in patients with subclinic hypothyroidism. Acta Biomed 2011;82:214-22.
  12. Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol 2009;29:424-30. https://doi.org/10.1161/ATVBAHA.108.181735
  13. Ridker PM, Genest J, Boekholdt SM, et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet 2010;376:333-9. https://doi.org/10.1016/S0140-6736(10)60713-1
  14. Barter PJ, Caufield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22. https://doi.org/10.1056/NEJMoa0706628
  15. AIM-HIGH Investigators, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-67. https://doi.org/10.1056/NEJMoa1107579
  16. Mora S, Glynn RJ, Ridker PM. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation 2013;128:1189-97. https://doi.org/10.1161/CIRCULATIONAHA.113.002671
  17. Mazer NA, Giulianini F, Paynter NP, Jordan P, Mora S. A comparison of the theoretical relationship between HDL size and the ratio of HDL cholesterol to apolipoprotein A-I with experimental results from the Women's Health Study. Clin Chem 2013;59:949-58. https://doi.org/10.1373/clinchem.2012.196949
  18. Nagila A, Permpongpaiboon T, Tantrarongroj S, et al. Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status. Pharmacol Rep 2009;61:892-8. https://doi.org/10.1016/S1734-1140(09)70146-X
  19. Miyamoto-Sasaki M, Yasuda T, Monguchi T, et al. Pitavastatin increases HDL particles functionally preserved with cholesterol efflux capacity and antioxidative actions in dyslipidemic patients. J Atheroscler Thromb 2013;20:708-16. https://doi.org/10.5551/jat.17210
  20. Harangi M, Seres I, Harangi J, Paragh G. Benefits and difficulties in measuring HDL subfractions and human paraoxonase-1 activity during statin treatment. Cardiovasc Drugs Ther 2009;23:501-10. https://doi.org/10.1007/s10557-009-6205-4
  21. Blatter MC, James RW, Messmer S, Barja F, Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem 1993;211:871-9. https://doi.org/10.1111/j.1432-1033.1993.tb17620.x
  22. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993;104:129-35. https://doi.org/10.1016/0021-9150(93)90183-U

Cited by

  1. THE EFFECT OF ATORVASTATINUM IN THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS vol.73, pp.11, 2016, https://doi.org/10.36740/wlek202011117